9 Best Promethease Alternatives in 2026 (Free & Paid)

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Genetic information should always be interpreted in consultation with a qualified healthcare provider. Variants discussed here represent statistical associations from population studies and may not predict individual outcomes.

---

Why People Are Looking for Promethease Alternatives in 2026

Promethease has been a cornerstone of the DIY genetics community since 2008. It was one of the first tools that let anyone upload raw DNA data from 23andMe or AncestryDNA and receive a report cross-referencing their variants against published research in SNPedia. For years, it was practically the only affordable option — a $12 report that put thousands of SNP associations at your fingertips.

But the landscape has changed substantially. In 2019, MyHeritage acquired Promethease and integrated it more tightly into its ecosystem. The user interface, long criticized for being dense and confusing to newcomers, received only modest updates. At the same time, a new generation of tools emerged offering cleaner interfaces, better curation, conversational AI layers, and more actionable interpretations.

People are now searching for alternatives for several distinct reasons:

• Report overwhelm. Promethease generates hundreds or thousands of genoset results, many of which are contradictory. A variant might show up as both "good" and "bad" for the same phenotype, depending on which study is cited. Without a genetics background, it is nearly impossible to know what to focus on.
• Static output. The report is a snapshot. You cannot ask follow-up questions, filter by health goal, or explore a specific gene in context. If you want to understand what your COMT rs4680 result actually means for your dopamine metabolism, you have to do that research yourself.
• Interface and UX. The text-heavy, table-based report format has not kept pace with modern expectations for data visualization and interactivity.
• Lack of clinical framing. Promethease cites literature associations but does not contextualize them within clinical guidelines, making it hard to distinguish a well-established pharmacogenomic finding from a single preliminary study.
• Cost vs. value questions. While $12 is inexpensive, users who want ongoing analysis — checking new research, exploring additional genes — find the model limiting.

This guide evaluates the most credible Promethease alternatives available in 2026, what each does well, where each falls short, and how to choose the right tool for your goals. We also cover which underlying databases power these tools, because that determines the quality of the science behind any report you receive.

---

What to Look for in a Promethease Alternative

Before comparing specific tools, it helps to define the criteria that matter for a serious genetic self-analysis platform. Not every tool needs to excel in all of these areas, but understanding the tradeoffs will help you match a tool to your specific use case.

Database quality and breadth

The scientific value of any consumer genomics interpretation tool depends almost entirely on the databases it queries. The major reference sources are:

• ClinVar — NCBI's archive of clinically interpreted variants, focusing on disease-associated mutations. Strong for pathogenic variants; less useful for wellness and trait SNPs.
• dbSNP — The reference database for single nucleotide polymorphisms, with population frequency data.
• SNPedia — A wiki-style database of SNP-phenotype associations curated from published literature. Powers Promethease directly.
• GWAS Catalog — The EBI/NHGRI catalog of genome-wide association studies, covering over 350,000 variant-trait associations.
• PharmGKB — The pharmacogenomics knowledge base, focused on drug-gene interactions with clinical annotations.
• gnomAD — Population allele frequencies across diverse ancestries, useful for contextualizing variant rarity.

Tools that rely solely on SNPedia inherit its strengths (broad literature coverage, community curation) and weaknesses (variable quality, limited clinical annotation). Tools that integrate PharmGKB add meaningful pharmacogenomics depth. Tools that query ClinVar provide better coverage of medically actionable pathogenic variants.

Report format: static vs. interactive

Static PDF or HTML reports have a fixed depth. Interactive platforms let you drill down, filter by phenotype category, or pose specific questions. For most users, the ability to ask "what does my MTHFR C677T result mean for folate metabolism?" in natural language is more useful than reading through 2,000 unfiltered genosets.

Pharmacogenomics coverage

This is one of the most clinically actionable areas of consumer genomics. Genes like CYP2D6, CYP2C19, CYP2C9, SLCO1B1, and DPYD directly influence how people metabolize dozens of common medications. Tools with strong PGx coverage — particularly those drawing from CPIC guidelines or PharmGKB — offer disproportionate value for the time invested.

Privacy and data handling

Raw DNA files contain information about you and your biological relatives. Before uploading to any platform, review: where the data is stored, whether it is sold or shared with third parties, how long it is retained, and whether you can delete it. Reputable platforms publish explicit privacy policies and offer data deletion on request.

Ancestry context

Population frequencies matter for interpreting variant significance. A variant with a 40% minor allele frequency in European populations is not "rare" in that group, even if a single paper flagged it as a risk factor. Tools that provide ancestry-adjusted allele frequencies (often drawing from gnomAD) give more calibrated results.

---

SelfDecode: Comprehensive Reports with AI Recommendations

SelfDecode is the most feature-complete Promethease alternative currently available. Founded by Joe Cohen (who previously ran SelfHacked), it has grown from a blog-adjacent tool into a full platform covering hundreds of health reports.

What it does: SelfDecode analyzes your raw DNA against its curated database and generates reports organized by health category — brain health, cardiovascular risk, hormones, sleep, inflammation, fitness, and more. Each report highlights your relevant variants, explains their functional effects, and provides prioritized supplement and lifestyle recommendations. The platform also includes a "DNA Mind" module for mental health genetics and has expanded into microbiome analysis.

Strengths:

• Well-designed, readable reports that non-scientists can understand
• Strong depth in functional medicine categories (methylation, detoxification, inflammation)
• AI assistant for asking questions about your results
• Active development with new reports added regularly
• Covers major actionable genes including MTHFR rs1801133, rs1801131; COMT rs4680; APOE rs429358, rs7412; BDNF rs6265

Weaknesses:

• Subscription model ($99–$197/year) is significantly more expensive than a one-time Promethease report
• Recommendations skew toward supplements, which reflects the platform's origins in functional medicine blogging
• Less transparent about underlying database sources than some alternatives
• Some reports are more evidence-based than others

Best for: Users who want a structured, category-organized analysis with actionable takeaways and are willing to pay for an ongoing subscription.

For a detailed comparison of SelfDecode against Promethease and Genetic Genie, see this dedicated breakdown. If you are specifically evaluating SelfDecode as a standalone Promethease replacement, the SelfDecode alternative guide for 2026 covers pricing changes and new features introduced this year.

---

Genetic Genie: Free Methylation and Detox Reports

Genetic Genie occupies a specific niche: free, focused reports on methylation and detoxification pathways. It does not attempt to be a comprehensive health analysis platform, which is both its limitation and its strength.

What it does: Upload your raw DNA (23andMe, AncestryDNA) and Genetic Genie generates a one-page methylation panel covering the core MTHFR pathway variants and related genes: MTHFR (rs1801133 C677T, rs1801131 A1298C), MTRR (rs1801394), MTR (rs1805087), COMT (rs4680, rs4633), VDR (rs2228570, rs731236, rs1544410), BHMT (rs3733890), CBS (rs234706, rs1801181), SHMT (rs1979277), and a handful of others.

The detox report covers CYP1A1, CYP1A2, CYP1B1, NAT1, NAT2, SOD2, GPX1, and GSTP1 variants involved in phase I and phase II liver detoxification.

Strengths:

• Completely free — no signup required
• Instant results
• Covers the specific variants most commonly discussed in functional medicine contexts
• Clean output format that practitioners familiar with methylation protocols can read quickly

Weaknesses:

• No clinical context, evidence grading, or caveats
• Reports the raw genotype without explaining effect direction or magnitude
• No pharmacogenomics, cardiovascular, or trait analysis
• The functional medicine framing of methylation variants is contested; not all cited associations are robustly replicated

Best for: People specifically interested in methylation pathway variants, particularly those working with integrative medicine practitioners who use these panels, and anyone who needs a free starting point before investing in a paid platform.

---

Xcode Life: Modular Reports by Health Category

Xcode Life offers a pay-per-report model that sits between Promethease's one-time fee and SelfDecode's subscription. Users purchase individual reports — nutrition, fitness, skin health, allergies, mental health, BRCA risk — rather than a single comprehensive export.

What it does: Each Xcode Life report focuses on a defined health category and delivers gene-by-gene analysis with straightforward explanations. The nutrition report covers things like FTO rs9939609 (obesity risk), APOA2 rs5082 (saturated fat sensitivity), FADS1/2 variants (omega-3 conversion efficiency), and TCF7L2 rs7903146 (type 2 diabetes risk). The fitness report covers ACTN3 rs1815739 (power vs. endurance), ACE rs4646994 (aerobic capacity), and PPARGC1A rs8192678 (training response).

Strengths:

• Modular purchasing — pay only for categories you care about
• Reports are accessible to lay readers
• Includes lifestyle and dietary recommendations contextualized to your genotype
• Covers a reasonable breadth of well-studied variants

Weaknesses:

• Individual reports range from $20–$30, so a comprehensive analysis across multiple categories can exceed SelfDecode's annual subscription cost
• Less depth per variant than SelfDecode's category reports
• No interactive or conversational layer

Best for: Users with focused questions in one or two health domains who prefer a la carte purchasing over subscriptions.

---

Genome Link and Genomelink: Trait-Based Analysis

Genomelink (rebranded from Awaken as Genome Link in some markets) takes a trait-focused approach, delivering bite-sized insights on dozens of physical and behavioral characteristics derived from GWAS data.

What it does: Rather than deep clinical reporting, Genomelink delivers quick results on traits like caffeine metabolism (CYP1A2 rs762551), lactose tolerance (MCM6 rs4988235), bitter taste perception (TAS2R38 rs713598), earwax type (ABCC11 rs17822931), circadian rhythm tendencies (CLOCK rs1801260), and athletic endurance (PPARA rs4253778). The platform now includes a premium tier with more detailed reports.

Strengths:

• Free tier provides a genuinely engaging introduction to what genetic data can reveal
• Clean, modern interface
• Good for sharing results with friends and family without overwhelming complexity
• Accurate trait calls for well-validated Mendelian or near-Mendelian traits

Weaknesses:

• Trait associations vary enormously in effect size and replication; the platform does not consistently distinguish robust findings from weaker ones
• Not designed for health or clinical use — no pharmacogenomics, no disease risk analysis
• Depth per trait is shallow

Best for: People new to genetics who want an engaging, low-stakes exploration of their raw data before committing to a deeper analysis tool.

---

Sequencing.com: Raw Data Vault with App Ecosystem

Sequencing.com operates as a DNA data repository and marketplace for analysis apps. Rather than providing its own analysis, it hosts a platform where third-party developers build and sell genetic apps that users can run on their stored data.

What it does: Upload your raw data once, then run any combination of apps from the Sequencing marketplace — apps covering methylation, pharmacogenomics, ancestry, fitness, nutrition, mental health, sleep, and more. Some apps are free; others are paid. The platform also offers whole genome sequencing services.

Strengths:

• Unified data storage: one upload, many analyses
• Broad app ecosystem covering niches that single-tool platforms miss
• Strong privacy positioning — users own and control their data
• Whole genome sequencing option provides higher resolution than microarray chips

Weaknesses:

• App quality varies significantly; there is no uniform evidence standard across the marketplace
• Requires evaluating individual apps rather than trusting a single platform's curation
• Interface is more complex than single-purpose tools
• Pricing structure can be confusing

Best for: Power users who want maximum flexibility and are willing to invest time curating their own analysis stack from multiple apps.

---

Pharmacogenomics-Focused Tools: GeneSight and Others

For users specifically interested in how their genetics affects medication response, pharmacogenomics platforms deserve separate consideration. This is arguably the highest-stakes area of consumer genetics, with direct clinical relevance for psychiatric medications, pain management, cardiac drugs, and anticoagulants.

GeneSight is the most clinically established PGx testing service in the US, offered through healthcare providers. It analyzes genes including CYP2D6, CYP2C19, CYP2C9, CYP3A4, SLC6A4, and HTR2A and provides reports in a format designed for prescribing clinicians. However, it requires ordering through a provider and uses its own proprietary testing rather than accepting raw DNA uploads.

For raw DNA upload PGx analysis, the most rigorous free option is the PharmGKB database itself, which allows manual lookup of your variants. This requires knowing which rs numbers to look up and understanding how to interpret star allele notation for genes like CYP2D6. It is not a report generator, but it is the primary source database that most consumer PGx tools draw from.

Key pharmacogenomically actionable variants commonly genotyped on consumer chips include:

• CYP2C19 rs4244285 (*2 allele — poor metabolizer of citalopram, clopidogrel, omeprazole)
• CYP2D6 rs3892097 (*4 allele — impacts codeine, tramadol, antidepressants, antipsychotics)
• CYP2C9 rs1799853 (*2), rs1057910 (*3) — warfarin, NSAIDs, phenytoin metabolism
• SLCO1B1 rs4149056 — statin-induced myopathy risk
• DPYD rs3918290 — fluorouracil toxicity risk
• TPMT rs1800460, rs1142345 — thiopurine toxicity (azathioprine, mercaptopurine)

Important caveat: Consumer microarray chips (23andMe, AncestryDNA) do not genotype all clinically relevant PGx variants. CYP2D6 in particular has structural variants and copy number variations that chips cannot detect. A clinical-grade PGx test from a CLIA-certified lab provides more reliable results for high-stakes medication decisions.

If you have already taken a consumer DNA test and want to extract PGx insights from your existing data, reading a full explanation of how to use your raw MTHFR data can help you understand what your chip data can and cannot tell you.

---

AI-Powered Conversational Analysis: A New Category

The most significant development in consumer genomics interpretation since 2020 is the emergence of conversational AI tools that can discuss your specific genetic variants in natural language. This addresses the core limitation of static reports: you cannot ask a Promethease output a follow-up question.

Traditional tools generate reports and leave interpretation to the user. Conversational AI platforms let you upload your raw DNA and then have an ongoing dialogue about your results — asking about specific genes, exploring the research behind a variant, understanding how multiple variants in a pathway interact, or getting context about what a result means for a particular health goal.

Ask My DNA is built specifically for this use case. You upload your 23andMe or AncestryDNA raw data, and then ask questions in plain English: "What does my APOE status mean for my long-term brain health?", "Do I have any variants affecting how I process caffeine?", or "What does my CYP2C19 result mean for antidepressant response?" The platform draws on your actual genotype data to provide personalized answers grounded in published research.

This approach has particular advantages for users who found Promethease overwhelming. Instead of receiving a 2,000-item report and trying to figure out what matters, you can start with the questions that are most relevant to your situation and explore from there. The platform offers 3 free questions with no credit card required, which makes it easy to evaluate whether the conversational format suits your needs before committing.

For users interested in translating their genetic data into actionable supplement or nutrition decisions, the guide on personalized supplements based on DNA covers how variants in MTHFR, VDR, FADS1, and COMT intersect with nutrient status and supplementation.

---

Head-to-Head Comparison Table

The following table summarizes the key dimensions across the tools discussed in this guide.

---

How to Choose the Right Tool for Your Goals

The best tool depends on what you actually want to do with your genetic data.

If you want to replicate the Promethease experience with a better interface: SelfDecode is the closest functional equivalent, with significantly better UX and more curated content. Expect to pay substantially more for the subscription.

If you have a specific health question: Start with Ask My DNA's free tier — 3 questions no credit card required — and ask exactly what you want to know. If your question is specifically about methylation and you work with a functional medicine practitioner, Genetic Genie's free report may be the fastest route.

If you care most about pharmacogenomics: Look for tools that explicitly draw from CPIC guidelines or PharmGKB. Understand the limitations of microarray data for CYP2D6. For high-stakes medication decisions, a clinical PGx test from a CLIA-certified lab is more reliable than any consumer report.

If you want to explore broadly without a fixed goal: Genomelink's free tier provides an engaging introduction. Sequencing.com gives maximum flexibility if you want to run multiple analyses over time without re-uploading your data.

If you have recently lost access to a platform: The article on what to do with 23andMe raw data after the bankruptcy covers how to retrieve and use your raw data across alternative platforms, and the best DNA upload sites for 2026 provides an up-to-date overview of where you can take your file.

If you have AncestryDNA data: Ancestry's chip does not include as many health-relevant SNPs as 23andMe v3/v4, but many variants are still present. The guide on AncestryDNA raw data health insights explains which health-relevant genes are covered and how to extract useful information from an Ancestry file.

---

Understanding the Limitations of All These Tools

Before acting on any result from any consumer genetics interpretation platform, it is important to understand several structural limitations that apply across all tools in this category.

Microarray coverage is incomplete. Consumer DNA tests genotype roughly 600,000–700,000 SNPs across the genome. The human genome contains approximately 3 billion base pairs and millions of common variants. Most structural variants, insertions, deletions, and variants in repetitive regions are not captured. Whole genome sequencing provides more complete coverage, though interpretation of the additional data is also more complex.

Association does not equal causation. Most consumer genetics variants are drawn from GWAS studies, which identify statistical correlations between variants and traits across large populations. A variant associated with 1.3x increased risk for a condition does not mean that person will develop the condition, or that the variant is mechanistically causing the association.

Effect sizes are usually small. Most common SNPs associated with complex traits like cardiovascular disease, type 2 diabetes, or depression have odds ratios between 1.05 and 1.3. These population-level signals do not translate cleanly to individual risk prediction. Polygenic risk scores — which aggregate thousands of small-effect variants — have better predictive validity than single-SNP interpretations.

Replication matters. SNPedia and similar databases include findings from single studies that have not been independently replicated. A finding that appears in one paper from 2009 with a sample size of 300 is categorically different from a finding in the GWAS Catalog with 100,000 subjects and multiple independent replications.

Ancestry affects interpretation. Allele frequencies differ substantially across ancestral populations. A variant that is strongly associated with a trait in a European GWAS cohort may have different or unknown effect in individuals of African, East Asian, or South Asian ancestry. Most consumer genomics databases have historically been dominated by European-ancestry studies, though this is gradually improving.

Rare pathogenic variants require clinical-grade testing. For diseases caused by rare, high-penetrance variants — BRCA1/2 for hereditary breast/ovarian cancer, LDLR mutations for familial hypercholesterolemia, MLH1/MSH2 for Lynch syndrome — consumer microarray chips do not sequence the full gene and will miss the majority of pathogenic variants. Clinical genetic testing through a certified laboratory and genetic counselor is the appropriate route for evaluating hereditary disease risk.

---

FAQ: Common Questions About Promethease Alternatives

Is there a free alternative to Promethease that covers the same range of SNPs?

No free tool currently covers the same breadth of SNP-phenotype associations as Promethease (which draws on SNPedia's ~100,000+ genosets). Genetic Genie is free but covers only methylation and detoxification genes. Genomelink offers a free tier focused on traits. For broad SNP coverage similar to Promethease at low cost, SelfDecode's subscription or Xcode Life's per-report model are the closest alternatives. Ask My DNA allows 3 free questions, which can efficiently surface the most relevant findings from your data without requiring you to process an entire report.

Can I use my 23andMe raw data with all of these tools?

Yes, all platforms discussed accept 23andMe raw data. AncestryDNA raw data is also accepted by most platforms. The main consideration is which version of the 23andMe chip you have — v3 and v4 chips include more health-relevant variants than the v5 chip released in 2017, which was optimized for ancestry. If you are unsure which version you have, your account settings show the chip version, or you can check by looking for the presence or absence of specific SNPs like APOE rs429358.

Are these tools HIPAA-compliant? How should I think about privacy?

Consumer genetics interpretation platforms are generally not covered entities under HIPAA (which applies to healthcare providers and their business associates), so HIPAA compliance is not the relevant standard. The applicable frameworks are each platform's privacy policy and, in the EU, GDPR. Key questions: Does the platform sell or share your genetic data with third parties? How long is data retained? Can you delete your account and have your data removed? Platforms like Sequencing.com and Ask My DNA publish explicit data retention and deletion policies. Always read the privacy policy before uploading raw DNA data.

What is the difference between a SNP report and whole genome sequencing?

Consumer DNA tests (23andMe, AncestryDNA) use microarray genotyping, which checks the presence or absence of known variant positions across the genome. This is cost-effective (tests cost $79–$199) but incomplete — it only looks at pre-selected positions, missing novel variants and most structural changes. Whole genome sequencing (WGS) reads every base pair, providing vastly more data and covering variants not targeted by microarrays. Clinical WGS typically costs $300–$1,000+. For most consumer health and trait analysis purposes, microarray data is sufficient for the variants currently associated with actionable phenotypes. WGS becomes more valuable when looking for rare pathogenic variants or when standard chip-based analysis has been uninformative.

How accurate are the recommendations from these tools?

Accuracy varies significantly by domain. Monogenic or near-monogenic traits — lactose tolerance (MCM6), earwax type (ABCC11), caffeine metabolism (CYP1A2) — can be predicted with high accuracy because effect sizes are large and well-replicated. Pharmacogenomic predictions for well-studied genes like CYP2C19 and CYP2C9 are clinically validated, though microarray chips may miss some relevant alleles. Complex disease risk scores for conditions like type 2 diabetes or cardiovascular disease reflect genuine population-level associations but have modest predictive value at the individual level. Treat recommendations based on complex polygenic traits as directional signals rather than prescriptions, and validate with a healthcare provider before making significant changes.

---

Conclusion

Promethease remains a legitimate and useful tool, but it is no longer the only serious option for raw DNA analysis. The alternatives available in 2026 span a wide range of formats, prices, and use cases — from free methylation-focused reports (Genetic Genie) to comprehensive subscription platforms (SelfDecode) to conversational AI analysis (Ask My DNA) to modular marketplaces (Sequencing.com).

The most important shift in this landscape is the move from static reports toward interactive, question-driven analysis. For most users, the ability to ask specific questions about their variants — and get answers that integrate their actual genotype with published research — is more useful than receiving a filtered dump of the entire SNP literature. If you have been sitting on raw DNA data without knowing how to interpret it, that barrier is now lower than it has ever been.

Whichever tool you choose, apply the same critical lens: check which databases power the analysis, understand the difference between well-replicated findings and preliminary associations, and consult a healthcare provider before making clinical decisions based on consumer genetics results. The goal is not to replace medical care but to become a more informed participant in it.

---

References:

1. Whirl-Carrillo M, et al. "Pharmacogenomics Knowledge for Personalized Medicine." Clinical Pharmacology & Therapeutics. 2021. PharmGKB

2. Landrum MJ, et al. "ClinVar: improving access to variant interpretations and supporting evidence." Nucleic Acids Research. 2018. ClinVar

3. Karczewski KJ, et al. "The mutational constraint spectrum quantified from variation in 141,456 humans." Nature. 2020. gnomAD

4. Buniello A, et al. "The NHGRI-EBI GWAS Catalog of published genome-wide association studies." Nucleic Acids Research. 2019. GWAS Catalog

5. Relling MV, Evans WE. "Pharmacogenomics in the clinic." Nature. 2015. PubMed

6. Bodenreider O. "The Unified Medical Language System (UMLS): integrating biomedical terminology." Nucleic Acids Research. 2004. NIH National Library of Medicine.